|Committee Member||Employment||Consultant||Speakers Bureau||Ownership/Partnership/Principal||Personal Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness||Voting Recusals∗|
|Loren F. Hiratzka, TAD, Chair||TriHealth Heart Institute—Medical Director, Cardiac Surgery||None||None||None||None||None||None||None|
|Rick A. Nishimura, VHD, Chair||Mayo Clinic, Division of Cardiovascular Disease—Judd and Mary Morris Leighton Professor of Medicine||None||None||None||None||None||None||None|
|Mark A. Creager, TAD Liaison||Dartmouth-Hitchcock Medical Center—Director, Heart and Vascular Center and Geisel School of Medicine at Dartmouth—Professor of Medicine||None||None||None||None||None||None||None|
|Robert A. Guyton, VHD Liaison||Emory Healthcare—Professor and Chief, Division of Cardiothoracic Surgery||None||None||None||None||None||Recused|
|Eric M. Isselbacher, TAD||Massachusetts General Hospital—Co-Director Thoracic Aortic Center; Harvard Medical School—Associate Professor of Medicine||None||None||None||None||None||None||None|
|Lars G. Svensson, TAD||Cleveland Clinic, Heart and Vascular Institute—Chairman; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University—Professor of Surgery||None||None||None||None||None||Recused|
|Robert O. Bonow, VHD||Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Cardiology||None||None||None||None||None||None||None|
|Thoralf M. Sundt III, VHD||Massachusetts General Hospital—Chief, Division of Cardiac Surgery; Harvard Medical School—Professor of Surgery||None||None||None||None||None||Recused|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.
ACC indicates American College of Cardiology; AHA, American Heart Association; PI, principal investigator; TAD, thoracic aortic disease; and VHD, valvular heart disease.